Review article

The role and research progress of microRNA in acute leukemia

Expand

Received date: 2022-12-08

  Online published: 2024-03-18

Cite this article

HUANG Rong, LIU Jing’an, ZHU Yilin, SHI Xiaofeng . The role and research progress of microRNA in acute leukemia[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(06) : 451 -456 . DOI: 10.16138/j.1673-6087.2023.06.014

References

[1] Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group[J]. Br J Haematol, 1976, 33(4): 451-458.
[2] Yamashita M, Dellorusso PV, Olson OC, et al. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis[J]. Nat Rev Cancer, 2020, 20(7): 365-382.
[3] Zhang Y, Zhou SY, Yan HZ, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1[J]. Sci Rep, 2016, 6: 19995.
[4] Krivdova G, Voisin V, Schoof EM, et al. Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML[J]. Cell Rep, 2022, 38(10): 110481.
[5] Zhang L, Nguyen LXT, Chen YC, et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance[J]. Nat Commun, 2021, 12(1): 6154.
[6] Zhu B, Zhong W, Cao X, et al. Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice[J]. Sci Transl Med, 2022, 14(629): eabh2548.
[7] Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia[J]. Proc Natl Acad Sci U S A, 2007, 104(50): 19971-19976.
[8] Zhu B, Xi X, Liu Q, et al. MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4[J]. Am J Transl Res, 2019, 11(6):3384-3397.
[9] Wang G, Yu X, Xia J, et al. MicroRNA-9 restrains the sharp increase and boost apoptosis of human acute myeloid leukemia cells by adjusting the Hippo/YAP signaling pathway[J]. Bioengineered, 2021, 12(1): 2906-2914.
[10] Huang J, Xiao R, Wang X, et al. MicroRNA-93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2[J]. Int J Oncol, 2021, 59(4): 81.
[11] Zhang R, Tang P, Wang F, et al. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway[J]. J Cell Biochem, 2019, 120(3): 4423-4432.
[12] Fu Y, Li L, Hou J, et al. miR-139-5p regulates the proliferation of acute promyelocytic leukemia cells by targeting MNT[J]. J Oncol, 2021, 2021: 5522051.
[13] Bao F, Zhang L, Pei X, et al. MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia[J]. PLoS One, 2021, 16(9): e0256995.
[14] Zhang Y, Chu X, Wei Q. MiR-451 promotes cell apoptosis and inhibits autophagy in pediatric acute myeloid leukemia by targeting HMGB1[J]. J Environ Pathol Toxicol Oncol, 2021, 40(2): 45-53.
[15] Tang YJ, Wu W, Chen QQ, et al. miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR[J]. BMC Cancer, 2022, 22(1): 909.
[16] Li SM, Zhao YQ, Hao YL, et al. Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2[J]. Eur Rev Med Pharmacol Sci, 2019, 23(3): 1203-1213.
[17] Qin Y, Wang Y, Liu D. miR-4792 inhibits acute myeloid leukemia cell proliferation and invasion and promotes cell apoptosis by targeting Kindlin-3[J]. Oncol Res, 2020, 28(4): 357-369.
[18] Wang Z, Luo H, Fang Z, et al. MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis[J]. BMB Rep, 2018, 51(9): 444-449.
[19] Zhang S, Zhang Q, Shi G, et al. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target[J]. Biomed Pharmacother, 2018, 97: 1189-1194.
[20] Wu F, Yin C, Qi J, et al. miR-362-5p promotes cell proliferation and cell cycle progression by targeting GAS7 in acute myeloid leukemia[J]. Hum Cell, 2020, 33(2): 405-415.
[21] Wang CJ, Zou H, Feng GF. MiR-10b regulates the proli-feration and apoptosis of pediatric acute myeloid leukemia through targeting HOXD10[J]. Eur Rev Med Pharmacol Sci, 2018, 22(21): 7371-7378.
[22] Li H, Tian X, Wang P, et al. MicroRNA-582-3p negatively regulates cell proliferation and cell cycle progression in acute myeloid leukemia by targeting cyclin B2[J]. Cell Mol Biol Lett, 2019, 24: 66.
[23] Zhang L, Wang X, Wu J, et al. MiR-335-3p inhibits cell proliferation and induces cell cycle arrest and apoptosis in acute myeloid leukemia by targeting EIF3E[J]. Biosci Biotechnol Biochem, 2021, 85(9): 1953-1961.
[24] Gao X, Fan S, Zhang X. MiR-1306-5p promotes cell proliferation and inhibits cell apoptosis in acute myeloid leukemia by downregulating PHF6 expression[J]. Leuk Res, 2022, 120: 106906.
[25] Zhou H, Jia X, Yang F, et al. miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6(CDK6)[J]. Bioengineered, 2021, 12(1): 4508-4519.
[26] Chen X, Yang S, Zeng J, et al. miR-1271-5p inhibits cell proliferation and induces apoptosis in acute myeloid leukemia by targeting ZIC2[J]. Mol Med Rep, 2019, 19(1): 508-514.
[27] Hu C, Yu M, Li C, et al. miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway[J]. Int J Biol Sci, 2020, 16(15): 2853-2867.
[28] Liang C, Li Y, Wang LN, et al. Up-regulated miR-155 is associated with poor prognosis in childhood acute lymphoblastic leukemia and promotes cell proliferation targeting ZNF238[J]. Hematology, 2021, 26(1): 16-25.
[29] Wang H, He H, Yang C. miR-342 suppresses the pro-liferation and invasion of acute myeloid leukemia by targeting Naa10p[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 3671-3676.
[30] Li C, Zhao T, Nie L, et al. MicroRNA-223 decreases cell proliferation, migration, invasion, and enhances cell apoptosis in childhood acute lymphoblastic leukemia via targeting Forkhead box O 1[J]. Biosci Rep, 2020, 40(10):BSR20200485.
[31] Almeida RS, Costa E Silva M, Coutinho LL, et al. MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia[J]. Hematol Oncol, 2019, 37(1):103-112.
[32] Mansouri S, Khansarinejad B, Mosayebi G, et al. Alteration in expression of miR-32 and FBXW7 tumor suppressor in plasma samples of patients with T-cell acute lymphoblastic leukemia[J]. Cancer Manag Res, 2020, 12:1253-1259.
[33] Zamani A, Fattahi Dolatabadi N, Houshmand M, et al. miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia[J]. Leuk Res, 2021, 109: 106643.
[34] Shahid S, Shahid W, Shaheen J, et al. Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia[J]. Sci Rep, 2021, 11(1): 22783.
[35] Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA[J]. Nucleic Acids Res, 2011, 39(16): 7223-7233.
[36] Zhang B, Pei Z, Wang H, et al. Clinical value of serum miRNA in patients with acute promyelocytic leukemia[J]. J Oncol, 2022, 2022: 7315879.
[37] Cao Y, Liu Y, Shang L, et al. Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia[J]. Int J Clin Oncol, 2022, 27(7): 1222-1232.
[38] Yu AM, Tu MJ. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination[J]. Pharmacol Ther, 2022, 230: 107967.
[39] Yu AM, Choi YH, Tu MJ. RNA drugs and RNA targets for small molecules: principles, progress, and challenges[J]. Pharmacol Rev, 2020, 72(4): 862-898.
[40] Seto AG, Beatty X, Lynch JM, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proli-feration and survival in cutaneous T-cell lymphoma[J]. Br J Haematol, 2018, 183(3): 428-444.
[41] Vu TT, St?lzel F, Wang KW, et al. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia[J]. Leukemia, 2021, 35(7): 1933-1948.
[42] Durmaz B, Bagca BG, Cogulu O, et al. Antileukemic effects of anti-miR-146a, anti-miR-155, anti-miR-181a, and prednisolone on childhood acute lymphoblastic leukemia[J]. Biomed Res Int, 2021, 2021: 3207328.
[43] Zhang H, Kang J, Liu L, et al. MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy[J]. Aging (Albany NY), 2020, 12(20): 20111-20126.
[44] Wang Z, Fang Z, Lu R, et al. MicroRNA-204 potentiates the sensitivity of acute myeloid leukemia cells to arsenic trioxide[J]. Oncol Res, 2019, 27(9): 1035-1042.
[45] Liu Y, Lei P, Qiao H, et al. miR-9 enhances the chemosensitivity of AML cells to daunorubicin by targeting the EIF5A2/MCL-1 axis[J]. Int J Biol Sci, 2019, 15(3): 579-586.
[46] Liu Y, Lei P, Qiao H, et al. MicroRNA-33b regulates sensitivity to daunorubicin in acute myelocytic leukemia by regulating eukaryotic translation initiation factor 5A-2[J]. J Cell Biochem, 2020, 121(1): 385-393.
[47] Bollaert E, Claus M, Vandewalle V, et al. MiR-15a-5p confers chemoresistance in acute myeloid leukemia by inhibiting autophagy induced by daunorubicin[J]. Int J Mol Sci, 2021, 22(10): 5153.
[48] Vandewalle V, Essaghir A, Bollaert E, et al. miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2[J]. J Cell Mol Med, 2021, 25(1): 575-585.
[49] Li Y, Zhang G, Wu B, et al. miR-199a-5p represses protective autophagy and overcomes chemoresistance by directly targeting DRAM1 in acute myeloid leukemia[J]. J Oncol, 2019, 2019: 5613417.
[50] Liu H, Liu M, Zhang J, et al. Downregulated miR-130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin[J]. Mol Med Rep, 2020, 22(4): 2810-2816.
[51] Cao YX, Wen F, Luo ZY, et al. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line[J]. J Cell Biochem, 2020, 121(10): 4022-4033.
[52] Long S, Ren D, Zhong F, et al. Reversal of glucocorticoid resistance in acute lymphoblastic leukemia cells by miR-145[J]. PeerJ, 2020, 8: e9337.
[53] Su YL, Wang X, Mann M, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo[J]. Blood, 2020, 135(3): 167-180.
Outlines

/